These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36499073)

  • 1. Increased Expression of the RBPMS Splice Variants Inhibits Cell Proliferation in Ovarian Cancer Cells.
    Rabelo-Fernández RJ; Noriega Rivera RA; Rivera YS; Tous-Beveraggi J; Valiyeva F; Vivas-Mejia PE
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.
    Rabelo-Fernández RJ; Santiago-Sánchez GS; Sharma RK; Roche-Lima A; Carrion KC; Rivera RAN; Quiñones-Díaz BI; Rajasekaran S; Siddiqui J; Miles W; Rivera YS; Valiyeva F; Vivas-Mejia PE
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
    Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
    Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
    Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
    J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of shRNA on Cisplatin-resistant Non-small Cell Lung Cancer Cell A549 via Silencing
    He L; Du ZD; Wang Y; Meng RQ; Zhao WW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):312-319. PubMed ID: 32543135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer cells.
    Santana-Rivera Y; Rabelo-Fernández RJ; Quiñones-Díaz BI; Grafals-Ruíz N; Santiago-Sánchez G; Lozada-Delgado EL; Echevarría-Vargas IM; Apiz J; Soto D; Rosado A; Meléndez L; Valiyeva F; Vivas-Mejía PE
    Am J Transl Res; 2020; 12(4):1275-1292. PubMed ID: 32355541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biological effect of down-regulating of MTRR gene on cisplatin-resistant ovarian cancer SKOV3 cells in vitro and in vivo studies].
    Chen J; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):126-34. PubMed ID: 26917482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SH3RF2 contributes to cisplatin resistance in ovarian cancer cells by promoting RBPMS degradation.
    Gong TT; Liu FH; Xiao Q; Li YZ; Wei YF; Xu HL; Cao F; Sun ML; Jiang FL; Tao T; Ma QP; Qin X; Song Y; Gao S; Wu L; Zhao YH; Huang DH; Wu QJ
    Commun Biol; 2024 Jan; 7(1):67. PubMed ID: 38195842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BIRC5 facilitates cisplatin-chemoresistance in a m
    Fan Y; Pan Y; Jia L; Gu S; Liu B; Mei Z; Lv C; Huang H; Zhu G; Deng Q
    Cancer Med; 2024 Jan; 13(1):e6811. PubMed ID: 38112021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TR3 modulates platinum resistance in ovarian cancer.
    Wilson AJ; Liu AY; Roland J; Adebayo OB; Fletcher SA; Slaughter JC; Saskowski J; Crispens MA; Jones HW; James S; Fadare O; Khabele D
    Cancer Res; 2013 Aug; 73(15):4758-69. PubMed ID: 23720056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circular RNA circPBX3 promotes cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression.
    Fu L; Zhang D; Yi N; Cao Y; Wei Y; Wang W; Li L
    Hum Cell; 2022 Sep; 35(5):1560-1576. PubMed ID: 35907138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells.
    Niimi K; Murakumo Y; Watanabe N; Kato T; Mii S; Enomoto A; Asai M; Asai N; Yamamoto E; Kajiyama H; Shibata K; Kikkawa F; Takahashi M
    Cancer Sci; 2014 May; 105(5):545-52. PubMed ID: 24597627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF111b, a C-terminal splice variant of VEGF-A and induced by mitomycin C, inhibits ovarian cancer growth.
    Li X; Gu F; Niu C; Wang Y; Liu Z; Li N; Pan B; He D; Kong J; Zhang S; Wang X; Yao Y; Zheng L
    J Transl Med; 2015 May; 13():164. PubMed ID: 25990504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.
    He X; Ee PL; Coon JS; Beck WT
    Clin Cancer Res; 2004 Jul; 10(14):4652-60. PubMed ID: 15269137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells.
    Wan J; Shi F; Xu Z; Zhao M
    Int J Oncol; 2015 Dec; 47(6):2217-25. PubMed ID: 26498997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
    Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
    Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.
    Huang MJ; Zhang W; Wang Q; Yang ZJ; Liao SB; Li L
    J Ovarian Res; 2018 Feb; 11(1):15. PubMed ID: 29433550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.